{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:15:47Z","timestamp":1778688947729,"version":"3.51.4"},"reference-count":24,"publisher":"Mattioli1885","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background: Vitiligo is a chronic autoimmune skin disorder characterized by loss of melanocytes, leading to depigmented patches. Though not physically harmful, its appearance causes significant psychological distress, especially in darker-skinned individuals. Topical therapies like tacrolimus, calcineurin inhibitor, are first-line treatment for localized, stable vitiligo. However, bimatoprost, a prostaglandin analog known for its melanogenic properties, is emerging as a potential alternative. The current study was done to compare efficacy and safety of topical bimatoprost 0.03% solution versus tacrolimus 0.1% ointment in management of stable vitiligo. Material &amp; Methods: A randomized comparative study was conducted over 24 months in Department of Dermatology at Era\u2019s Lucknow Medical College. Fifty clinically stable vitiligo patients (aged &gt;18 years, &lt;5% BSA involvement) were randomized into two groups: Group A received topical bimatoprost 0.03%, and Group B received topical tacrolimus 0.1%, both applied twice daily over lesions. Treatment was continued for 12 weeks, with follow-up every 4 weeks. Efficacy was assessed using the Vitiligo Area Scoring Index (VASI), Subjective score and Photographic documentation. Any side effects were documented at each follow-up. Results: Both groups showed clinical improvement, with Group A demonstrating faster onset of repigmentation, particularly in facial lesions. Bimatoprost was well-tolerated with minimal side effects such as local hypertrichosis, while tacrolimus was associated with mild burning in some cases. Conclusion: Topical bimatoprost 0.03% is a safe and effective alternative to tacrolimus 0.1% ointment in treating stable vitiligo, especially for cosmetically sensitive areas. Therefore, it can be considered as a treatment option in stable vitiligo.<\/jats:p>","DOI":"10.5826\/dpc.1602a6256","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:48:09Z","timestamp":1777571289000},"page":"6256","source":"Crossref","is-referenced-by-count":0,"title":["Comparative study on the therapeutic efficacy of topical bimatoprost (0.03%) ophthalmic solution and tacrolimus (0.1%) ointment in stable vitiligo."],"prefix":"10.5826","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6932-3963","authenticated-orcid":false,"given":"Riya","family":"Kalawat","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venerology & Leprosy, Eras Lucknow Medical College & Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-0121","authenticated-orcid":false,"given":"Kshitij","family":"Saxena","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venerology & Leprosy, Eras Lucknow Medical College & Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyan Abdul","family":"Jamil","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venerology & Leprosy, Eras Lucknow Medical College & Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-7896","authenticated-orcid":false,"given":"Dilshad Ali","family":"Rizvi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Eras Lucknow Medical College & Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketki","family":"Ketki","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venerology & Leprosy, Eras Lucknow Medical College & Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9173-5069","authenticated-orcid":false,"given":"Bhavika","family":"Bansal","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venerology & Leprosy, Eras Lucknow Medical College & Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarjeet","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology & Leprosy, NCR Institute of Medical Sciences, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"10.5826\/dpc.1602a6256_ref1","doi-asserted-by":"crossref","unstructured":"Marchioro HZ, Silva de Castro CC, Fava VM, et al. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022;97(4):478\u2013490. DOI:10.1016\/j.abd.2021.09.002","DOI":"10.1016\/j.abd.2021.09.008"},{"key":"10.5826\/dpc.1602a6256_ref2","doi-asserted-by":"crossref","unstructured":"Hu Z, Wang T. Beyond skin white spots: Vitiligo and associated comorbidities. Front Med (Lausanne). 2023;10:1072837. DOI:10.3389\/fmed.2023.1072837","DOI":"10.3389\/fmed.2023.1072837"},{"key":"10.5826\/dpc.1602a6256_ref3","doi-asserted-by":"crossref","unstructured":"Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: A meta-analysis. PLoS One. 2016;11(9):e0163806. DOI:10.1371\/journal.pone.0163806","DOI":"10.1371\/journal.pone.0163806"},{"key":"10.5826\/dpc.1602a6256_ref4","doi-asserted-by":"crossref","unstructured":"Alikhan A, Felsten LM, Daly M, et al. Vitiligo: A comprehensive overview. Part I. J Am Acad Dermatol. 2011;65(3):473\u2013491. DOI:10.1016\/j.jaad.2010.11.061","DOI":"10.1016\/j.jaad.2010.11.061"},{"key":"10.5826\/dpc.1602a6256_ref5","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo. Int J Dermatol. 2012;51(10):1206\u20131212. DOI:10.1111\/j.1365-4632.2011.05377.x","DOI":"10.1111\/j.1365-4632.2011.05377.x"},{"key":"10.5826\/dpc.1602a6256_ref6","doi-asserted-by":"crossref","unstructured":"Akl J, Lee S, Ju HJ, et al. Estimating the burden of vitiligo. Lancet Public Health. 2024;9(6):e386\u2013e396. DOI:10.1016\/S2468-2667(24)00064-4","DOI":"10.1016\/S2468-2667(24)00026-4"},{"key":"10.5826\/dpc.1602a6256_ref7","doi-asserted-by":"crossref","unstructured":"Iacovelli P, Sinagra JL, Paro Vidolin A, et al. Relevance of thyroiditis in children with vitiligo. Dermatology. 2005;210(1):26\u201330. DOI:10.1159\/000081484","DOI":"10.1159\/000081479"},{"key":"10.5826\/dpc.1602a6256_ref8","doi-asserted-by":"crossref","unstructured":"Kartal D, Borlu M, \u00c7\u0131nar SL, et al. Thyroid abnormalities in paediatric vitiligo. Postepy Dermatol Alergol. 2016;33(3):232\u2013234. DOI:10.5114\/ada.2016.60616","DOI":"10.5114\/ada.2016.60617"},{"key":"10.5826\/dpc.1602a6256_ref9","doi-asserted-by":"crossref","unstructured":"Njoo MD, Westerhof W. Vitiligo: Pathogenesis and treatment. Am J Clin Dermatol. 2001;2(3):167\u2013181.","DOI":"10.2165\/00128071-200102030-00006"},{"key":"10.5826\/dpc.1602a6256_ref10","doi-asserted-by":"crossref","unstructured":"Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005;25(Suppl):63\u201368. DOI:10.1016\/j.jaut.2005.09.001","DOI":"10.1016\/j.jaut.2005.10.001"},{"key":"10.5826\/dpc.1602a6256_ref11","doi-asserted-by":"crossref","unstructured":"Pathak GN, Tan IJ, Bai G, et al. Vitiligo: From mechanisms to treatable pathways. Skin Health Dis. 2024;4:e460. DOI:10.1002\/ski2.460","DOI":"10.1002\/ski2.460"},{"key":"10.5826\/dpc.1602a6256_ref12","doi-asserted-by":"crossref","unstructured":"Dellatorre G, Antelo DAP, Bedrikow RB, et al. Consensus on the treatment of vitiligo. An Bras Dermatol. 2020;95(Suppl 1):70\u201382. DOI:10.1016\/j.abd.2020.03.011","DOI":"10.1016\/j.abd.2020.05.007"},{"key":"10.5826\/dpc.1602a6256_ref13","doi-asserted-by":"crossref","unstructured":"Speeckaert R, van Geel N. Vitiligo: An update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18(6):733\u2013744. DOI:10.1007\/s40257-017-0293-7","DOI":"10.1007\/s40257-017-0298-5"},{"key":"10.5826\/dpc.1602a6256_ref14","doi-asserted-by":"crossref","unstructured":"Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416\u2013425. DOI:10.4103\/2229-5178.142483","DOI":"10.4103\/2229-5178.142483"},{"key":"10.5826\/dpc.1602a6256_ref15","doi-asserted-by":"crossref","unstructured":"Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47(5):789\u2013791. DOI:10.1067\/mjd.2002.124697","DOI":"10.1067\/mjd.2002.126250"},{"key":"10.5826\/dpc.1602a6256_ref16","doi-asserted-by":"crossref","unstructured":"Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: A comprehensive overview. Part II: Treatment options and approach to treatment. J Am Acad Dermatol. 2011;65(3):493\u2013514. DOI:10.1016\/j.jaad.2010.11.062","DOI":"10.1016\/j.jaad.2010.10.043"},{"key":"10.5826\/dpc.1602a6256_ref17","doi-asserted-by":"crossref","unstructured":"Tran C, Lubbe J, Sorg O, et al. Topical calcineurin inhibitors decrease UVB-induced damage. Dermatology. 2005;211(4):341\u2013347. DOI:10.1159\/000088498","DOI":"10.1159\/000088505"},{"key":"10.5826\/dpc.1602a6256_ref18","doi-asserted-by":"crossref","unstructured":"Silpa-Archa N, Likittanasombat S, Apinuntham C, et al. The efficacy of bimatoprost with NB-UVB in vitiligo. Sci Rep. 2023;13(1):6438. DOI:10.1038\/s41598-023-33788-7","DOI":"10.1038\/s41598-023-32591-8"},{"key":"10.5826\/dpc.1602a6256_ref19","doi-asserted-by":"crossref","unstructured":"Jha AK, Sinha R, Prasad S, et al. Bimatoprost in periorbital vitiligo. J Eur Acad Dermatol Venereol. 2016;30(7):1247\u20131248. DOI:10.1111\/jdv.13105","DOI":"10.1111\/jdv.13176"},{"key":"10.5826\/dpc.1602a6256_ref20","doi-asserted-by":"crossref","unstructured":"Kanokrungsee S, Pruettivorawongse D, Rajatanavin N. Clinical outcomes of topical bimatoprost in facial vitiligo. J Cosmet Dermatol. 2021;20(3):812\u2013818. DOI:10.1111\/jocd.13664","DOI":"10.1111\/jocd.13648"},{"key":"10.5826\/dpc.1602a6256_ref21","doi-asserted-by":"crossref","unstructured":"Pruettivorawongse D, Kanokrungsee S, Ratchatanawin N. Comparison of bimatoprost and tacrolimus in vitiligo. J Am Acad Dermatol. 2018;79(3):AB82.","DOI":"10.1016\/j.jaad.2018.05.359"},{"key":"10.5826\/dpc.1602a6256_ref22","doi-asserted-by":"crossref","unstructured":"Kumari A, Kumar A, Manohar M, et al. Comparison of tacrolimus versus bimatoprost in vitiligo. Int J Pharm Sci Rev Res. 2024;84(10):37\u201341.","DOI":"10.47583\/ijpsrr.2024.v84i10.007"},{"key":"10.5826\/dpc.1602a6256_ref23","doi-asserted-by":"crossref","unstructured":"Zaky MS, Atallah RB, El Abasy NTA, et al. Comparative study of excimer light with tacrolimus versus bimatoprost. Arch Dermatol Res. 2024;316(7):350. DOI:10.1007\/s00403-024-02926-2","DOI":"10.1007\/s00403-024-03054-5"},{"key":"10.5826\/dpc.1602a6256_ref24","doi-asserted-by":"crossref","unstructured":"Das SK, Majumder PP, Chakraborty R, et al. Epidemiological profile of vitiligo in India. Genet Epidemiol. 1985;2(1):71\u201378. DOI:10.1002\/gepi.1370020109","DOI":"10.1002\/gepi.1370020107"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6256\/3807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6256\/3807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:47:23Z","timestamp":1778687243000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/6256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1602a6256","relation":{"has-manifestation":[{"id-type":"other","id":"1-83-6256-g3807","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1602a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"22"}}